

HIMS · NYSE · WEEK ENDED 24 JUL 2026

Weekly Investor Report

Hims Hers Health Inc · Healthcare · Drug Manufacturers - Specialty & Generic

LATEST CLOSE

28.09 USD

-14.5% latest week

Weekly setup

Mixed setup

The weekly trend is active. Price is 7.0% above the Trend Line and sits at 25.3% of its 52-week range. The latest completed week returned -14.5%, after a -17.2% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth ranks strongly; valuation is expensive relative to peers. Options positioning is mixed with 42/100 conviction, while the latest news-sentiment score is 49/100. Near-term considerations: earnings are due in 4d.

Technical setup score 29/100. This score describes the weekly technical setup; the conclusion above also considers fundamentals, positioning, sentiment, and event risk.

LATEST CLOSE

28.09 USD

24 Jul 2026

1W RETURN

-14.5%

latest completed week

4W RETURN

-17.2%

short-term follow-through

12W RETURN

2.5%

quarterly tape

TREND BREADTH

28.8%

15 of 52 weeks active

VOLUME RATIO

1.0x

vs 13-week average

What is working

- The trend backdrop is active with a 3-week active streak.
- Price is above the Trend Line, keeping the weekly tape constructive.
- Price is above Fair Value, showing premium demand versus the model.
- Activity pressure is positive on the latest completed week.

What could go wrong

- The share remains more than 20% below its 52-week high.
- The latest week was a sharp negative move.

What to watch next

- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.

This week's evidence at a glance

PRICE FOLLOW-THROUGH

-14.5%

Latest completed week; four-week move -17.2%.

INDICATOR STACK

26/70

Trend and activity pressure are weighted against the latest 12-week confirmation window.

TREND BACKDROP

Active

The trend backdrop defines the current weekly regime.

PATIENT CAPITAL

Quiet

Activity-pressure buy-signal status for institutional accumulation timing.

OPTIONS PRESSURE

Mixed

42/100 conviction; expected move 11.4%.

NEWS SENTIMENT

49/100

50 relevant articles in the latest sentiment read.

EVENT RISK

4d


Next report is scheduled for 03 Aug 2026; event risk rises as the date approaches.

01 · PRICE ACTION

Where price is—and whether the trend supports it

The weekly trend is active. Price is 7.0% above the Trend Line and sits at 25.3% of its 52-week range. The latest completed week returned -14.5%, after a -17.2% four-week move.

52-week price path



Blue: weekly close · Green: Trend Line · Orange: Sharemaestro Fair Value

Position in the 52-week range 13.74 USD 70.43 USD Latest close sits at 25.3% of the 52-week range.	RANGE LOCATION 25.3% Shows where the latest close sits between the 52-week low and high.	TREND DISTANCE 7.0% Price premium or discount versus the weekly Trend Line.
	FAIR-VALUE GAP 5.5% Premium demand or model discount versus Sharemaestro Fair Value.	HIGH-WATER GAP -60.1% Distance from the latest 52-week high.


02 · VOLUME AND DEMAND

Is real participation confirming the move?

Latest weekly volume is 1.0x the 13-week average. Participation is around or above normal and provides reasonable confirmation.

26-week volume confirmation

Bar height shows weekly volume. Green marks an up week; orange marks a down week.



PARTICIPATION	BASELINE	ONE-YEAR BASE	LATEST WEEKLY VOLUME
1.0x	91.4M	129.2M	87.5M
Latest volume versus the 13-week average.	13-week average volume.	52-week average volume.	Most recent completed week.

Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath price. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.47 · 12-week average 0.24

12-week confirmation


Signal	Read	Meaning
Trend active	3/12	Active trend-backdrop weeks in the latest 12-week window.
Positive pressure	12/12	Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership	0/12	Weeks with positive relative leadership in the latest 12-week window.
Activity pressure	0.47	Current proprietary activity-pressure read.
Buy signals	0	Accumulation signal count in the latest 12 weeks.
Reversal markers	0	No reversal markers

No recent accumulation markers. No reversal markers.

03 · MOMENTUM AND LEADERSHIP

Is performance persistent—and is the stock leading?

Performance is -17.2% over four weeks, 2.5% over 12 weeks, and -51.3% over one year. The current trend has remained active for 3 consecutive weeks.



Technical setup scorecard

Trend		26
Momentum		13
Activity Pressure		70
Relative Leadership		0
Next-Week Expectancy		50
Volume		40
Smart Money		33
Risk Control		0

04 · FUNDAMENTALS AND VALUATION

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth ranks strongly; valuation is expensive relative to peers.

FACTOR WEEK 26 Jul 2026 Latest published factor snapshot.	STATEMENTS THROUGH 31 Dec 2025 Financial reporting period used.	FIELD COVERAGE 88% Available factor fields.	MODEL CONFIDENCE 84% Snapshot confidence.
--	--	--	--

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength		4/100
Value		17/100
Quality		24/100
Momentum		6/100
Growth		83/100

Valuation How much investors are paying for earnings, sales, and cash flow. <table><tr><td>P/E</td><td>-</td></tr><tr><td>Price divided by trailing earnings.</td><td></td></tr><tr><td>PRICE / SALES</td><td>2.7x</td></tr><tr><td>Market value relative to trailing revenue.</td><td></td></tr><tr><td>EV / EBITDA</td><td>246.6x</td></tr><tr><td>Enterprise value relative to operating cash earnings.</td><td></td></tr><tr><td>FREE-CASH-FLOW YIELD</td><td>6.6%</td></tr><tr><td>Free cash flow as a share of enterprise value.</td><td></td></tr></table>	P/E	-	Price divided by trailing earnings.		PRICE / SALES	2.7x	Market value relative to trailing revenue.		EV / EBITDA	246.6x	Enterprise value relative to operating cash earnings.		FREE-CASH-FLOW YIELD	6.6%	Free cash flow as a share of enterprise value.		Business quality Margins and the return generated on invested capital. <table><tr><td>GROSS MARGIN</td><td>67.6%</td></tr><tr><td>Gross profit retained from each unit of revenue.</td><td></td></tr><tr><td>OPERATING MARGIN</td><td>-1.6%</td></tr><tr><td>Operating profit retained from revenue.</td><td></td></tr><tr><td>FREE-CASH-FLOW MARGIN</td><td>20.7%</td></tr><tr><td>Free cash flow generated from revenue.</td><td></td></tr><tr><td>RETURN ON INVESTED CAPITAL</td><td>-2.1%</td></tr><tr><td>Operating return generated on invested capital.</td><td></td></tr></table>	GROSS MARGIN	67.6%	Gross profit retained from each unit of revenue.		OPERATING MARGIN	-1.6%	Operating profit retained from revenue.		FREE-CASH-FLOW MARGIN	20.7%	Free cash flow generated from revenue.		RETURN ON INVESTED CAPITAL	-2.1%	Operating return generated on invested capital.	
P/E	-																																
Price divided by trailing earnings.																																	
PRICE / SALES	2.7x																																
Market value relative to trailing revenue.																																	
EV / EBITDA	246.6x																																
Enterprise value relative to operating cash earnings.																																	
FREE-CASH-FLOW YIELD	6.6%																																
Free cash flow as a share of enterprise value.																																	
GROSS MARGIN	67.6%																																
Gross profit retained from each unit of revenue.																																	
OPERATING MARGIN	-1.6%																																
Operating profit retained from revenue.																																	
FREE-CASH-FLOW MARGIN	20.7%																																
Free cash flow generated from revenue.																																	
RETURN ON INVESTED CAPITAL	-2.1%																																
Operating return generated on invested capital.																																	

04 · FUNDAMENTALS AND VALUATION · CONTINUED

Growth, shareholder returns, and balance-sheet strength

The second half of the fundamental read separates recent business growth from cash returned to shareholders and financial leverage.

Growth and financial strength	Shareholder return and balance sheet
Recent business growth and accounting strength.	Cash returned to owners and financial leverage.
REVENUE GROWTH32.8%	DIVIDEND YIELD-
Latest one-year revenue growth.	Cash dividends relative to market value.
EPS GROWTH-	BUYBACK YIELD1.1%
Latest one-year earnings-per-share growth.	Net share repurchases relative to market value.
FREE-CASH-FLOW GROWTH13.7%	SHAREHOLDER YIELD1.1%
Latest one-year free-cash-flow growth.	Dividend yield plus net buyback yield.
PIOTROSKI F-SCORE4/9	NET DEBT / EBITDA30.3x
Nine-point accounting-strength checklist.	Balance-sheet debt relative to operating cash earnings.

How to read this

Quality and valuation are separate questions. A strong company can still carry a demanding valuation, so profitability, growth, balance-sheet strength, and the price paid for those characteristics should be assessed independently.

The latest factor snapshot indicates quality is middle-of-the-pack; growth ranks strongly; valuation is expensive relative to peers.

05 · OWNERSHIP, OPTIONS, AND SENTIMENT

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioning

Mixed

HIMS shows mixed options pressure with a 42/100 conviction score, put-call volume ratio of 0.88, expected move of 11.4%, and Sharemaestro trend signal active.

CONVICTION

42/100

Options signal conviction.

EXPECTED MOVE

11.4%

Nearest-chain pricing.

PUT/CALL VOLUME

0.88

Contract volume balance.

Pressure

11

Speculation

44

Volatility

96

Trend agreement

71

Insider activity

9 / 11

9 acquisitions and 11 disposals in the latest 180-day insider tape. Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.

News sentiment

49/100

Weighted news tone is neutral across 50 relevant articles.

7 positive · 35 neutral · 8 negative

Patient Capital

Quiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows. No recent buy signal

06 · CATALYSTS AND RISK

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly gains and losses frame the risk around the current setup.

NEXT EARNINGS
4d
Next report is scheduled for 03 Aug 2026; event risk rises as the date approaches.


OPTIONS EXPECTED MOVE
11.4%
Nearest-chain priced movement where available.

52-WEEK DRAWDOWN
-60.1%
Distance below the 52-week high.

13-WEEK VOLATILITY
11.7%
Standard deviation of weekly returns.

Weekly gains and losses

Each bar is one completed week. Gains rise above zero; losses fall below it. Taller bars mean a larger move.



WEEKS HIGHER
11 of 26
15 weeks finished lower.

BEST WEEK
+57.4%
Week of 13 Mar.

WORST WEEK
-29.2%
Week of 13 Feb.

LATEST WEEK
-14.5%
Week of 24 Jul.

Shape of recent returns

Strong gains		7
Modest gains		4
Flat weeks		-
Modest losses		1
Sharp losses		14

RECENT VOL
11.7%
13-week weekly-return volatility.

BASE VOL
14.4%
52-week weekly-return volatility.

UP/DOWN SPLIT
18/34
Count of positive and negative weeks in the 52-week window.

AVERAGE SKEW
13.2% / -7.7%
Average positive week versus average negative week.

07 · SECTOR AND PEER CONTEXT

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

Sector · US Healthcare

4-WEEK RANK	GROUP AVERAGE	TREND BREADTH
- / 100	1.3%	51.0%
Standing within the tracked group.	Average four-week return.	Share of peers with an active trend.

Peer	Exchange	1W return	4W return	Trend
ABVX	NASDAQ	-8.0%	28.9%	Active
THC	NYSE	19.6%	23.4%	Inactive
BBIO	NASDAQ	3.2%	19.6%	Active
ONC	NASDAQ	4.4%	16.4%	Inactive
MEDP	NASDAQ	11.8%	14.1%	Inactive

Industry · US Drug Manufacturers - Specialty & Generic

4-WEEK RANK	GROUP AVERAGE	TREND BREADTH
69 / 74	-1.2%	37.8%
Standing within the tracked group.	Average four-week return.	Share of peers with an active trend.

Peer	Exchange	1W return	4W return	Trend
ZYBT	NASDAQ	147.9%	142.5%	Inactive
TLPH	NASDAQ	1.9%	31.1%	Active
CABR	NASDAQ	11.5%	19.8%	Active
ETON	NASDAQ	0.6%	19.3%	Active
OPTH	NASDAQ	-6.6%	14.4%	Inactive

08 · EVIDENCE AND WEEKLY DATA

The underlying research record

Every top-level statement should be traceable to a stored market, fundamental, event, or positioning observation.

Cross-signal evidence matrix

Evidence pillar	Score / read	Summary	Detail
Weekly tape	32/100	Trend, activity pressure, participation, and risk combine to a 32/100 tape read.	
Indicator analysis	44/100	Latest 12-week confirmation: trend 3/12, activity pressure 12/12, relative leadership 0/12.	Activity pressure 0.47; No reversal markers
Factors	12/100	O'Shaughnessy factor stack blends value, quality, momentum, and confidence.	Buyback Yield rank 30; Small Cap Core rank 94
Patient Capital	Quiet	Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.	No recent buy signal
Options	54/100	HIMS shows mixed options pressure with a 42/100 conviction score, put-call volume ratio of 0.88, expected move of 11.4%, and Sharemaestro trend signal active.	Mixed · Options-market disagreement · Expected move 11.4%
Sentiment	49/100	Weighted news tone is neutral across 50 relevant articles.	Hims & Hers Health, Inc. (HIMS) Stock Drops Despite Market Gains: Important Facts to Note
Insiders	9 / 11	9 acquisitions and 11 disposals in the latest 180-day insider tape.	
Earnings	4d	Next report is scheduled for 03 Aug 2026; event risk rises as the date approaches.	

Current evidence clusters

PRICE FOLLOW-THROUGH -14.5% Latest completed week; four-week move -17.2%.	INDICATOR STACK 26/70 Trend and activity pressure are weighted against the latest 12-week confirmation window.	TREND BACKDROP Active The trend backdrop defines the current weekly regime.	PATIENT CAPITAL Quiet Activity-pressure buy-signal status for institutional accumulation timing.
OPTIONS PRESSURE Mixed 42/100 conviction; expected move 11.4%.	NEWS SENTIMENT 49/100 50 relevant articles in the latest sentiment read.	EVENT RISK 4d Next report is scheduled for 03 Aug 2026; event risk rises as the date approaches.	

08 · EVIDENCE AND WEEKLY DATA · CONTINUED

Recent completed weeks

The completed weekly bars behind the report provide a compact audit trail for price, trend, Fair Value, activity pressure, leadership, and volume.

Week	Close	Return	Trend Line	Fair Value	Pressure	Leadership	Volume	Trend
24 Jul 2026	28.09 USD	-14.5%	26.26 USD	26.63 USD	1.06	-25.82	87.5M	On
17 Jul 2026	32.84 USD	-4.5%	26.46 USD	26.50 USD	1.28	-15.48	57.0M	On
10 Jul 2026	34.38 USD	-6.6%	26.55 USD	26.35 USD	1.32	-14.05	59.7M	On
03 Jul 2026	36.80 USD	8.4%	26.65 USD	26.18 USD	1.18	-7.82	72.0M	Off
26 Jun 2026	33.94 USD	-4.3%	26.73 USD	26.00 USD	0.99	-14.01	84.6M	Off
19 Jun 2026	35.47 USD	32.3%	26.92 USD	25.84 USD	0.85	-13.34	100.1M	Off
12 Jun 2026	26.82 USD	2.4%	26.90 USD	25.67 USD	0.68	-35.27	89.1M	Off
05 Jun 2026	26.19 USD	0.2%	27.24 USD	25.55 USD	0.68	-37.67	92.1M	Off
29 May 2026	26.15 USD	10.1%	27.73 USD	25.44 USD	0.68	-40.52	73.0M	Off
22 May 2026	23.75 USD	-5.2%	28.37 USD	25.33 USD	0.69	-46.30	106.1M	Off
15 May 2026	25.05 USD	-11.4%	29.21 USD	25.24 USD	0.82	-44.03	179.7M	Off
08 May 2026	28.27 USD	3.1%	30.03 USD	25.14 USD	0.87	-38.19	90.0M	Off
01 May 2026	27.41 USD	-10.3%	30.89 USD	25.03 USD	0.66	-39.69	97.1M	Off
24 Apr 2026	30.56 USD	6.0%	31.73 USD	24.93 USD	0.41	-32.84	249.0M	Off

How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown in the fundamentals section.

Educational market research only. Not financial, investment, trading, tax, or legal advice. Market data, indicators, summaries, and reports may be delayed, incomplete, or inaccurate. You are responsible for your own decisions and should seek independent professional advice where appropriate.
Open the live report · Open the interactive chart · Full disclaimer